[go: up one dir, main page]

PE20090889A1 - Derivados de tomaimicina como agentes citotoxicos - Google Patents

Derivados de tomaimicina como agentes citotoxicos

Info

Publication number
PE20090889A1
PE20090889A1 PE2008001200A PE2008001200A PE20090889A1 PE 20090889 A1 PE20090889 A1 PE 20090889A1 PE 2008001200 A PE2008001200 A PE 2008001200A PE 2008001200 A PE2008001200 A PE 2008001200A PE 20090889 A1 PE20090889 A1 PE 20090889A1
Authority
PE
Peru
Prior art keywords
iloximethyl
benzodiazepin
ona
tetrahydro
phenoxy
Prior art date
Application number
PE2008001200A
Other languages
English (en)
Inventor
Herve Bouchard
Alain Commercon
Laurence Gauzy
Ravi V J Chari
Yonghong Deng
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39048765&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090889(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20090889A1 publication Critical patent/PE20090889A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE TOMAIMICINA DE FORMULA I, DONDE ---- ES ENLACE SIMPLE OPCIONAL; U Y U' SON CADA UNO H O ESTAN AUSENTES; W Y W' SON CADA UNO H, -OH, -OR, ENTRE OTROS; R ES H, ALQUILO, ARILO, ENTRE OTROS; R1, R2, R1' Y R2' SON CADA UNO H, HALURO O ALQUILO, ENTRE OTROS; X Y X' SON CADA UNO -O-, -S-, -(C=O)-, ENTRE OTROS; A Y A' SON CADA UNO ALQUILO O ALQUENILO, ENTRE OTROS; Y E Y' SON CADA UNO H O OR; T ES -NR-, CICLOALQUILO, HETEROCICLO, ENTRE OTROS; n Y n' SON CADA UNO 0 O 1. SON COMPUESTOS PREFERIDOS: ACIDO 4-(3,5-BIS-[(S)-2-ET-(E)-ILIDEN-7-METOXI-1,2,3,11a-TETRAHIDRO-PIRROLO[2,1c][1.4]BENZODIAZEPIN-5-ONA-8-ILOXIMETIL]-FENOXI)-BUTIRICO, ACIDO 4-(3,5-BIS-[(S)-2-ET-(E)-ILIDEN-7-METOXI-1,2,3,11a-TETRAHIDRO-PIRROLO[2,1c][1.4]BENZODIAZEPIN-5-ONA-8-ILOXIMETIL]-FENOXI)-ACETICO, ACIDO 3-(2-{2-[2-(3,5-BIS-[(S)-2-ET-(E)-ILIDEN-7-METOXI-1,2,3,11a-TETRAHIDRO-PIRROLO[2,1c][1.4]BENZODIAZEPIN-5-ONA-8-ILOXIMETIL]-FENOXI)-ETOXI}-ETOXI)-PROPIONICO, ENTRE OTROS. SE REFIERE TAMBIEN A PROCEDIMIENTOS PARA SU PREPARACION Y A UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE. DICHOS COMPUESTOS SE UNEN MEDIANTE ENLACES COVALENTES A UN AGENTE DE UNION A LA CELULA, SIENDO UTILES PARA LA ELIMINACION DE CELULAS ENFERMAS O ANORMALES QUE DEBEN DESTRUIRSE O LISARSE, TALES COMO LAS CELULAS TUMORALES (PARTICULARMENTE CELULAS DE TUMOR SOLIDO)
PE2008001200A 2007-07-19 2008-07-16 Derivados de tomaimicina como agentes citotoxicos PE20090889A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07290904.7A EP2019104B1 (en) 2007-07-19 2007-07-19 Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use

Publications (1)

Publication Number Publication Date
PE20090889A1 true PE20090889A1 (es) 2009-08-06

Family

ID=39048765

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2008001200A PE20090889A1 (es) 2007-07-19 2008-07-16 Derivados de tomaimicina como agentes citotoxicos
PE2013000171A PE20130590A1 (es) 2007-07-19 2008-07-16 Derivados de tomaimicina como agentes citotoxicos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2013000171A PE20130590A1 (es) 2007-07-19 2008-07-16 Derivados de tomaimicina como agentes citotoxicos

Country Status (39)

Country Link
US (1) US8404678B2 (es)
EP (2) EP2019104B1 (es)
JP (1) JP5551070B2 (es)
KR (1) KR101627871B1 (es)
CN (1) CN101784550B (es)
AR (1) AR067575A1 (es)
AT (1) ATE530553T1 (es)
AU (1) AU2008281439B2 (es)
BR (1) BRPI0814267A2 (es)
CA (1) CA2693551C (es)
CL (1) CL2008002139A1 (es)
CO (1) CO6290692A2 (es)
CR (1) CR11225A (es)
CY (2) CY1112278T1 (es)
DK (2) DK2019104T3 (es)
DO (1) DOP2010000014A (es)
EA (1) EA019938B1 (es)
EC (1) ECSP109875A (es)
ES (2) ES2435779T3 (es)
GT (1) GT201000008A (es)
HR (1) HRP20120067T1 (es)
IL (1) IL203318A (es)
JO (1) JO2744B1 (es)
MA (1) MA31617B1 (es)
ME (1) ME00969B (es)
MY (1) MY151245A (es)
NI (1) NI201000005A (es)
NZ (1) NZ582679A (es)
PA (1) PA8790201A1 (es)
PE (2) PE20090889A1 (es)
PL (2) PL2019104T3 (es)
PT (2) PT2019104E (es)
RS (1) RS52245B (es)
SI (2) SI2019104T1 (es)
TN (1) TN2010000002A1 (es)
TW (1) TWI500618B (es)
UA (1) UA98153C2 (es)
WO (1) WO2009016516A2 (es)
ZA (1) ZA201000389B (es)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3826769A1 (de) 1988-08-06 1990-02-15 Bayer Ag Behandlung von polyamidfasern
EP2662096A1 (en) 2005-08-24 2013-11-13 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2009014910A2 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
DE102008056086A1 (de) * 2008-11-06 2010-05-12 Gp Solar Gmbh Additiv für alkalische Ätzlösungen, insbesondere für Texturätzlösungen sowie Verfahren zu dessen Herstellung
EP2393362B1 (en) * 2009-02-05 2016-08-24 Immunogen, Inc. Novel benzodiazepine derivatives
AU2015224492B2 (en) * 2009-02-05 2017-04-20 Immunogen, Inc. Novel benzodiazepine derivatives
PT2437790T (pt) 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) * 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
AU2011239522B2 (en) 2010-04-15 2014-10-23 Medimmune Limited Targeted pyrrolobenzodiazapine conjugates
WO2011130598A1 (en) * 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
JP5875083B2 (ja) 2010-04-15 2016-03-02 メディミューン リミテッド 増殖性疾患治療用ピロロベンゾジアゼピン
JP5847813B2 (ja) 2010-06-23 2016-01-27 シマベイ セラピューティクス， インコーポレーテッド ５−エチル−２−｛４−［４−（４−テトラゾル−１−イル−フェノキシメチル）−チアゾール−２−イル］−ピペリジン−１−イル｝−ピリミジンの組成物
FR2963007B1 (fr) * 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
PL2675479T3 (pl) 2011-02-15 2016-09-30 Cytotoksyczne pochodne benzodiazepiny
CN107537040A (zh) 2011-03-29 2018-01-05 伊缪诺金公司 通过一步法制备类美登素抗体缀合物
WO2012145112A2 (en) 2011-04-18 2012-10-26 Immunogen, Inc. Novel maytansinoid derivatives with sulfoxide linker
AU2012311505B2 (en) 2011-09-20 2016-09-29 Medimmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
JP6170497B2 (ja) 2011-10-14 2017-07-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン
EA026643B1 (ru) 2011-10-14 2017-04-28 Сиэтл Дженетикс, Инк. Пирролбензодиазепины и конъюгаты направленного действия
CN103987384A (zh) 2011-10-14 2014-08-13 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
CA2850264C (en) 2011-10-14 2019-11-05 Spirogen Sarl Pyrrolobenzodiazepines
HK1203364A1 (en) * 2011-12-13 2015-10-30 Immunogen, Inc. Use of n-hydroxysuccinimide to improve conjugate stability
AR090549A1 (es) 2012-03-30 2014-11-19 Genentech Inc Anticuerpos anti-lgr5 e inmunoconjugados
TW201402609A (zh) 2012-05-01 2014-01-16 Genentech Inc 抗ｐｍｅｌ１７抗體及免疫結合物
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
EP2869850B1 (en) 2012-07-09 2017-08-23 Genentech, Inc. Immunoconjugates comprising anti-cd79b antibodies
MX2015000357A (es) 2012-07-09 2015-05-12 Genentech Inc Anticuerpos e inmunoconjugados anti-cd22.
MX2015001399A (es) 2012-08-02 2015-09-07 Genentech Inc Anticuerpos anti-etbr e inmunoconjugados.
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
AU2013326881B2 (en) * 2012-10-04 2018-08-02 Immunogen, Inc. Use of a PVDF membrane to purify cell-binding agent cytotoxic agent conjugates
CA2885305C (en) 2012-10-12 2019-11-12 Spirogen Sarl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
ES2680153T3 (es) 2012-10-12 2018-09-04 Adc Therapeutics Sa Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
EP2906251B1 (en) 2012-10-12 2017-09-27 ADC Therapeutics SA Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
JP6392763B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
TR201808051T4 (tr) 2012-10-12 2018-06-21 Adc Therapeutics Sa Pirrolobenzodiazepin antikor konjugatları.
CA3060520C (en) 2012-10-12 2022-05-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
MX364330B (es) * 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
EP2968494B1 (en) 2013-03-13 2018-11-14 Seattle Genetics, Inc. Activated carbon filtration for purification of benzodiazepine adcs
KR102057755B1 (ko) * 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
BR112015022019A2 (pt) 2013-03-14 2017-08-29 Genentech Inc Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
CN105636612B (zh) 2013-08-12 2020-01-14 基因泰克公司 抗体-药物缀合物及使用和治疗方法
HK1218124A1 (zh) 2013-09-17 2017-02-03 豪夫迈．罗氏有限公司 使用抗lgr5抗体的方法
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
WO2015052534A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
PE20160712A1 (es) 2013-12-13 2016-07-26 Genentech Inc Anticuerpos e inmunoconjugados anti-cd33
CN105828840B (zh) 2013-12-16 2020-08-04 基因泰克公司 1-(氯甲基)-2,3-二氢-1H-苯并[e]吲哚二聚体抗体-药物缀合物化合物及使用和治疗方法
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
MX2016015162A (es) 2014-05-22 2017-03-03 Genentech Inc Anticuerpos anti - gpc3 e inmunoconjugados.
JP7286267B2 (ja) 2014-08-28 2023-06-05 バイオアトラ インコーポレイテッド 修飾ｔ細胞に対する条件的活性型キメラ抗原受容体
EA034138B1 (ru) 2014-09-03 2020-01-09 Иммуноджен, Инк. Цитотоксические бензодиазепиновые производные
JP2017527562A (ja) 2014-09-03 2017-09-21 イミュノジェン・インコーポレーテッド 細胞毒性ベンゾジアゼピン誘導体
AU2015314744A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
HUE052460T2 (hu) 2014-09-12 2021-04-28 Genentech Inc Anti-HER2 antitestek és immunkonjugátumok
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
KR20170052600A (ko) 2014-09-12 2017-05-12 제넨테크, 인크. 시스테인 가공된 항체 및 콘주게이트
US10059768B2 (en) 2014-09-12 2018-08-28 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
WO2016044396A1 (en) * 2014-09-17 2016-03-24 Genentech, Inc. Immunoconjugates comprising anti-her2 antibodies and pyrrolobenzodiazepines
MX379396B (es) * 2014-11-25 2025-03-11 Adc Therapeutics Sa Conjugados de pirrolobenzodiazepina y anticuerpo.
AU2016206798A1 (en) 2015-01-14 2017-08-31 Bristol-Myers Squibb Company Benzodiazepine dimers, conjugates thereof, and methods of making and using
TW201632532A (zh) 2015-01-14 2016-09-16 必治妥美雅史谷比公司 伸雜芳基－橋聯苯并二氮呯二聚體，其共軛物及製造及使用方法
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
EP3307749A4 (en) 2015-06-15 2019-06-19 Hangzhou Dac Biotech Co., Ltd HYDROPHILIC LINKER FOR CONJUGATION
CN108391434A (zh) 2015-06-23 2018-08-10 百时美施贵宝公司 大环苯并二氮杂*二聚体、其缀合物、制备和用途
EP4678240A2 (en) 2015-07-12 2026-01-14 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
SI3325482T1 (sl) 2015-07-21 2020-11-30 Immunogen, Inc. Postopki za pripravo citotoksičnih benzodiazepinskih derivatov
US11078286B2 (en) 2015-09-20 2021-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use
MA43354A (fr) 2015-10-16 2018-08-22 Genentech Inc Conjugués médicamenteux à pont disulfure encombré
CN107405408B (zh) * 2015-12-21 2021-07-02 江苏恒瑞医药股份有限公司 一种抗体药物偶联物的制备方法
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
KR102697688B1 (ko) 2016-04-15 2024-08-21 바이오아트라, 인코퍼레이티드 항 Axl항체 및 이의 면역접합체와 이것들의 용도
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
PT3455261T (pt) 2016-05-13 2022-11-11 Bioatla Llc Anticorpos anti-ror2, fragmentos de anticorpo, seus imunoconjugados e suas utilizações
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CN107469089B (zh) * 2016-06-07 2022-01-07 北京键凯科技股份有限公司 一种peg连接子及配基药物偶联物
AU2017305170A1 (en) 2016-08-02 2019-02-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
EP3493807A1 (en) 2016-08-03 2019-06-12 CymaBay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CN109689111B (zh) 2016-08-11 2024-04-05 基因泰克公司 吡咯并苯并二氮杂䓬前药及其抗体缀合物
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
MX2019005583A (es) 2016-11-14 2019-10-21 Hangzhou Dac Biotech Co Ltd Vinculantes de conjugacion, conjugados de molecula de union a celulas que contienen los vinculantes, metodos de creacion y usos de dichos conjugados con los vinculantes.
KR102221364B1 (ko) 2016-11-21 2021-03-04 쿠레아브 게엠베하 항-gp73　항체　및　면역접합체
JP7203729B2 (ja) 2016-11-23 2023-01-13 イミュノジェン・インコーポレーテッド ベンゾジアゼピン誘導体の選択的スルホン化
EP4219556A3 (en) 2016-12-21 2023-10-11 The United States of America as represented by The Secretary Department of Health and Human Services Human monoclonal antibodies specific for flt3 and uses thereof
LT3558391T (lt) 2016-12-23 2022-07-11 Immunogen, Inc. Imunokonjugatai, kurių taikinys yra adam9, ir jų naudojimo būdai
TW201825515A (zh) 2017-01-04 2018-07-16 美商伊繆諾金公司 Ｍｅｔ抗體以及其免疫結合物及用途
WO2018146189A1 (en) 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
RS63502B1 (sr) 2017-04-18 2022-09-30 Medimmune Ltd Konjugati pirolobenzodiazepina
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
EP3625256A1 (en) 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
AU2018285562B2 (en) 2017-06-14 2024-01-18 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
WO2019006280A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. HUMAN MONOCLONAL ANTIBODIES SPECIFIC TO CD33 AND METHODS OF USE
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
WO2019023247A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND
HRP20220311T1 (hr) 2017-08-18 2022-05-13 Medimmune Limited Konjugati pirolobenzodiazepina
SG11202001430SA (en) 2017-09-29 2020-04-29 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
EP3732178A1 (en) 2017-12-28 2020-11-04 ImmunoGen, Inc. Benzodiazepine derivatives
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
AU2019301675B2 (en) 2018-07-12 2025-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured CD22-specific monoclonal antibody and uses thereof
CA3106544A1 (en) 2018-08-08 2020-02-13 Mitchell Ho High affinity monoclonal antibodies targeting glypican-2 and uses thereof
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途
IL312067B2 (en) 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
WO2020141923A2 (ko) * 2019-01-03 2020-07-09 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도
WO2020146182A1 (en) 2019-01-08 2020-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross-species single domain antibodies targeting mesothelin for treating solid tumors
CA3125033A1 (en) 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN116063505B (zh) 2019-01-30 2024-05-03 真和制药有限公司 抗gal3抗体及其用途
EP3938372B1 (en) 2019-03-15 2023-10-25 MedImmune Limited Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer
US20230094471A1 (en) 2019-03-29 2023-03-30 Immunogen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
AU2020370125A1 (en) 2019-10-22 2022-05-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity nanobodies targeting B7H3 (CD276) for treating multiple solid tumors
MX2022006713A (es) 2019-12-06 2022-07-12 Truebinding Inc Anticuerpos que interrumpen la interaccion entre gal3 y receptor de insulina o integrinas y metodos de uso de los mismos.
JP7679380B2 (ja) 2019-12-12 2025-05-19 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｃｄ２７６に特異的な抗体－薬物コンジュゲートおよびその使用
AU2021237465A1 (en) 2020-03-19 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating Facioscapulohumeral muscular dystrophy
AU2021241682A1 (en) 2020-03-27 2022-10-13 Avidity Biosciences, Inc. Compositions and methods of treating muscle dystrophy
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022261017A1 (en) 2021-06-09 2022-12-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
EP4370555A4 (en) 2021-07-13 2025-11-12 Truebinding Inc METHODS FOR PREVENTING PROTEIN AGGREGATION
WO2023043953A1 (en) 2021-09-16 2023-03-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합
CN118524852A (zh) 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
IL316223A (en) 2022-05-03 2024-12-01 Genentech Inc Anti-LY6E antibodies, immunoconjugates and their uses
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
EP4509142A1 (en) 2023-08-16 2025-02-19 Ona Therapeutics S.L. Fgfr4 as target in cancer treatment
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1516743A (fr) 1966-04-01 1968-02-05 Rhone Poulenc Sa Nouvel antibiotique et son procédé de préparation par culture de streptomyces croceus
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
ES2149768T3 (es) * 1992-03-25 2000-11-16 Immunogen Inc Conjugados de agentes enlazantes de celulas derivados de cc-1065.
ATE240334T1 (de) 1998-08-27 2003-05-15 Spirogen Ltd Pyrrolobenzodiazepine
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
EP1242401B1 (en) * 1999-11-24 2006-12-27 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6756397B2 (en) * 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
AU2003285878B2 (en) 2002-11-07 2011-04-28 Immunogen, Inc. Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
EP1608663B1 (en) * 2003-03-31 2008-11-05 Council of Scientific and Industrial Research Pyrrolo (2,1-c)(1,4) benzodiazepines dimers as antitumour agents and process thereof
WO2004091542A2 (en) 2003-04-15 2004-10-28 Covx Pharmaceuticals, Inc. Nitrogen containing integrin targeting compounds
ES2360403T3 (es) 2003-07-21 2011-06-03 Immunogen, Inc. Conjugado citotóxico específico para el antígeno ca6 y métodos para usar el mismo.
GB0321295D0 (en) * 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
AU2004284075A1 (en) * 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
GB0404578D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
GB0404577D0 (en) * 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
JP5166861B2 (ja) 2004-03-09 2013-03-21 スピロゲン リミティッド ピロロベンゾジアゼピン
GB0410725D0 (en) * 2004-05-13 2004-06-16 Spirogen Ltd Pyrrolobenzodiazepine therapeutic agents
SI1813614T1 (sl) * 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
MX2009000709A (es) * 2006-07-18 2009-02-04 Sanofi Aventis Anticuerpo antagonista contra epha2 para el tratamiento de cancer.
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
RS52245B (sr) 2012-10-31
KR20100063021A (ko) 2010-06-10
MY151245A (en) 2014-04-30
SI2019104T1 (sl) 2013-12-31
EA201070163A1 (ru) 2010-08-30
HRP20120067T1 (hr) 2012-02-29
TN2010000002A1 (en) 2011-09-26
CN101784550B (zh) 2014-06-11
NZ582679A (en) 2012-04-27
DOP2010000014A (es) 2010-02-15
CY1114922T1 (el) 2016-12-14
WO2009016516A3 (en) 2009-06-11
BRPI0814267A2 (pt) 2015-03-31
NI201000005A (es) 2010-03-09
JP5551070B2 (ja) 2014-07-16
GT201000008A (es) 2012-03-26
PE20130590A1 (es) 2013-05-22
SI2170890T1 (sl) 2012-02-29
ECSP109875A (es) 2010-02-26
CY1112278T1 (el) 2015-12-09
MA31617B1 (fr) 2010-08-02
WO2009016516A2 (en) 2009-02-05
ZA201000389B (en) 2011-04-28
CN101784550A (zh) 2010-07-21
AR067575A1 (es) 2009-10-14
UA98153C2 (uk) 2012-04-25
DK2170890T3 (da) 2012-02-27
EP2170890A2 (en) 2010-04-07
AU2008281439B2 (en) 2013-02-07
CA2693551A1 (en) 2009-02-05
ATE530553T1 (de) 2011-11-15
JO2744B1 (en) 2014-03-15
TWI500618B (zh) 2015-09-21
PT2019104E (pt) 2013-12-03
DK2019104T3 (da) 2013-12-16
CA2693551C (en) 2016-09-20
TW200922598A (en) 2009-06-01
CL2008002139A1 (es) 2009-10-23
ES2376026T3 (es) 2012-03-08
CO6290692A2 (es) 2011-06-20
CR11225A (es) 2010-06-23
JP2010533703A (ja) 2010-10-28
PT2170890E (pt) 2012-02-03
HK1144289A1 (en) 2011-02-11
EA019938B1 (ru) 2014-07-30
PL2019104T3 (pl) 2014-03-31
EP2019104A1 (en) 2009-01-28
IL203318A (en) 2016-08-31
ES2435779T3 (es) 2013-12-23
WO2009016516A8 (en) 2009-04-16
KR101627871B1 (ko) 2016-06-07
US20100316656A1 (en) 2010-12-16
US8404678B2 (en) 2013-03-26
PA8790201A1 (es) 2009-02-09
EP2170890B1 (en) 2011-10-26
EP2019104B1 (en) 2013-09-04
ME00969B (me) 2012-06-20
PL2170890T3 (pl) 2012-04-30
AU2008281439A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
PE20090889A1 (es) Derivados de tomaimicina como agentes citotoxicos
CO6612267A2 (es) Nuevos derivados de 1,1 dióxido- 5 fenil- 2,3,4-5tetrahidro- 1,4-benzotiazepina y composiciones farmaceúticas que los comprenden
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
PE20121732A1 (es) Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes
PE20121088A1 (es) Nuevos compuestos eficaces como inhibidores de la xantina-oxidasa, metodo para la preparacion de los mismos y composicion farmaceutica que los contiene
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
PE20050628A1 (es) DERIVADOS DE 2-AMINO-PIRIDINA COMO AGONISTAS ß-2
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
PE20120797A1 (es) Derivados de 1-[(3'-fluoro-4'-hidroximetil-5'-metilsulfonil)bifenil-4-il]-2-bencil-4-[(1-hidroxi-1-metil)etil]-1h-imidazol como moduladores de lxr
EP2058317A4 (en) AMINOOPHOSPHORIC ACID DERTER DERIVATIVE AND THIS ACTIVE MODULATOR OF THE S1P RECEPTOR
UY32660A (es) Derivados aminobutricos sustituidos como inhibidores de neprilisina
CU20130082A7 (es) 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
UY33075A (es) Derivados de ciclohexano y usos de los mismos
AR074002A1 (es) Pirazolo e imidazopiridinilpirimidinaminas como inhibidores de la tirosina kinasa (igr-ir)
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
CL2024000758A1 (es) Sal de trometamina de ácido 2-[4-[(5,6-difenilpirazin-2-il)-propan-2-ilamino]butoxi]acético
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF
BRPI0409809A (pt) formulação farmacêutica do sal de sódio de telmisartano
DK2164492T3 (da) Trans-4-{2-[4-(2,3-dichlorphenyl)-piperazin-1-yl]-ethyl}-N,N-dimethylcarbamoylcyclohexylamin til behandling af skizofreni
AR068921A1 (es) Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros.
EP2722042A4 (en) INDANO DERIVATIVES, PHARMACEUTICALLY ALLOWED SALTS OR OPTICAL ISOMERS THEREOF, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFORE AS AN ACTIVE AGENT FOR THE PREVENTION OR TREATMENT OF VIRUS DISEASES
DK1843754T3 (da) Ny farmaceutisk sammensætning indeholdende candesartan-cilexetil som lipofilt krystallinsk stof
CA2427750A1 (en) Substituted alkanoic acids

Legal Events

Date Code Title Description
FC Refusal